Literature DB >> 2547869

IL-4 induces LFA-1 and LFA-3 expression on Burkitt's lymphoma cell lines. Requirement of additional activation by phorbol myristate acetate for induction of homotypic cell adhesions.

F Rousset1, M Billaud, D Blanchard, C Figdor, G M Lenoir, H Spits, J E De Vries.   

Abstract

LFA-1 and LFA-3 expression is absent or low on Burkitt's lymphoma cell lines and low on the EBV-transformed B cell line UD61. Incubation of cells of BL2 and of UD61 with various concentrations of IL-4 resulted in induction of LFA-1 and LFA-3 expression in a dose dependent fashion. This effect was already observed after 16 h of incubation whereas maximal expression was obtained after 72 h. Induction of LFA-1 and LFA-3 expression seemed to be specific for IL-4, because IL-1, IL-2, IL-3, IFN-alpha, IFN-gamma and a low m.w. B cell growth factor were ineffective. LFA-1 and LFA-3 induction by IL-4 was blocked specifically by an anti-IL-4 antiserum. Induction of LFA-1 expression by IL-4 was furthermore confirmed at the specific LFA-1 beta-chain mRNA level. IL-4 was unable to induce LFA-1 expression on EBV-transformed lymphoblastoid cell lines of two LFA-1-deficient patients. BL2 grows as single cells, but induction of LFA-1 and LFA-3 expression by IL-4 was insufficient to induce homotypic cell adhesions and required PMA as a second signal. PMA alone did not induce LFA-1 antigen expression and was unable to induce adhesions between BL2 cells in the absence of IL-4 in 22 h assays. Addition of PMA to BL2 cells that expressed LFA-1 Ag upon incubation with IL-4 resulted in aggregate formation within 30 min. Adhesions between BL2 cells induced by IL-4 in combination with PMA were blocked by anti-LFA-1 beta or anti-LFA-1 alpha-chains mAb. In addition, these mAbs dispersed preformed aggregates of BL2 cells. Our results indicate that IL-4 can induce the adhesion molecules LFA-1 and LFA-3 on B cell lines, but that an additional activation signal provided by PMA was required for the induction of homotypic cell adhesions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2547869

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Interleukin-4. A regulatory protein.

Authors:  J H Jansen; W E Fibbe; R Willemze; J C Kluin-Nelemans
Journal:  Blut       Date:  1990-05

2.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.

Authors:  F Wang; C Gregory; C Sample; M Rowe; D Liebowitz; R Murray; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  Rapid cytokine up-regulation of integrins, complement receptor 1 and HLA-DR on monocytes but not on lymphocytes.

Authors:  G A Limb; A S Hamblin; R A Wolstencroft; D C Dumonde
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

4.  Adhesion receptor profile of thymic B-cell lymphoma.

Authors:  A Eichelmann; K Koretz; G Mechtersheimer; P Möller
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

Review 5.  Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

Authors:  G Tosato; J Teruya-Feldstein; J Setsuda; S E Pike; K D Jones; E S Jaffe
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Interleukin-4-mediated aggregation of anti-IgM-stimulated human B cells: inhibition of aggregation but enhancement of proliferation by antibodies to LFA-1.

Authors:  P Björck; S Paulie; B Axelsson
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

Review 7.  CD58 Immunobiology at a Glance.

Authors:  Yalu Zhang; Qiaofei Liu; Sen Yang; Quan Liao
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

8.  Interleukin 4 is localized to and released by human mast cells.

Authors:  P Bradding; I H Feather; P H Howarth; R Mueller; J A Roberts; K Britten; J P Bews; T C Hunt; Y Okayama; C H Heusser
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

9.  ADP-dependent glucokinase as a novel onco-target for haematological malignancies.

Authors:  Amol Tandon; Jana Birkenhagen; Deepthi Nagalla; Stefan Kölker; Sven Wolfgang Sauer
Journal:  Sci Rep       Date:  2020-08-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.